Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:6212
Name ovarian endometrial cancer
Definition An ovary epithelial cancer that has_material_basis_in the endometrium and is located_in the ovary.
Source DiseaseOntology.org
Alt Ids DOID:4116
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer ovarian endometrial cancer


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01844986 Phase III Olaparib Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS 7
NCT02068794 Phase Ib/II MV-NIS MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting USA 0
NCT02345265 Phase II Cediranib + Olaparib Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Completed USA | CAN 0
NCT03395080 Phase II DKN-01 DKN-01 + Paclitaxel A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204) Completed USA 0
NCT03462212 Phase Ib/II Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) Recruiting ITA 0
NCT03602859 Phase III Dostarlimab-gxly + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 10
NCT04261465 Phase II Carboplatin + Olaparib + Paclitaxel NUVOLA TRIAL Open-label Multicentre Study (NUVOLA) Unknown status ITA 0
NCT04460807 Phase III Exemestane Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT) Terminated ITA 0
NCT04669002 Phase II NLG207 + Olaparib EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Completed USA | GBR 1
NCT04729387 Phase III Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT04931342 Phase II Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT05065021 Phase II Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor Recruiting CAN 0
NCT05295589 Phase II Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Withdrawn USA 0